PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, and mega virtual library screening to support the discovery of novel hit compounds; custom synthesis (FFS); and full time equivalent (FTE). The company also provides small molecule drug substance CDMO services, including optimal route scouting; FFS and FTE for process research and development of RSMs, intermediates, and APIs; impurity studies and synthesis; solid state chemistry; analytical development and quality control; cGMP manufacturing of intermediates and APIs; and CMC regulatory filing support. In addition, it offers small molecule DP CDMO services, such as candidate screening and selection, early development, full development, registration, and post-approval; and new modality services, including target protein degrader, peptide, oligonucleotide, and ADC services. PharmaBlock Sciences (Nanjing), Inc. was founded in 2006 and is based in Nanjing, the People's Republic of China.
Research context
PharmaBlock Sciences (Nanjing), Inc appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
PharmaBlock Sciences (Nanjing), Inc is currently in a long term uptrend where the price is trading 13.5% above its 200 day moving average.
From a valuation standpoint, the stock is 133.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 22.5.
PharmaBlock Sciences (Nanjing), Inc's total revenue rose by 49.9% to $297M since the same quarter in the previous year.
Its net income has increased by 20.9% to $42M since the same quarter in the previous year.
Finally, its free cash flow grew by 1440.3% to $65M since the same quarter in the previous year.
Based on the above factors, PharmaBlock Sciences (Nanjing), Inc gets an overall score of 4/5.